Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Contineum Therapeutics (CTNM) EBITDA (2023 - 2026)

Contineum Therapeutics' EBITDA history spans 4 years, with the latest figure at -$15.0 million for Q1 2026.

  • Quarterly EBITDA rose 5.8% to -$15.0 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$58.9 million through Mar 2026, down 18.68% year-over-year, with the annual reading at -$59.8 million for FY2025, 41.36% down from the prior year.
  • EBITDA came in at -$15.0 million for Q1 2026, up from -$15.2 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $41.5 million in Q2 2023 to a low of -$16.1 million in Q2 2025.
  • The 4-year median for EBITDA is -$9.6 million (2024), against an average of -$7.2 million.
  • Year-over-year, EBITDA crashed 121.87% in 2024 and then grew 5.8% in 2026.
  • Contineum Therapeutics' EBITDA stood at -$7.6 million in 2023, then crashed by 98.82% to -$15.1 million in 2024, then fell by 0.7% to -$15.2 million in 2025, then increased by 1.27% to -$15.0 million in 2026.
  • Per Business Quant, the three most recent readings for CTNM's EBITDA are -$15.0 million (Q1 2026), -$15.2 million (Q4 2025), and -$12.7 million (Q3 2025).